Business
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
WATERTOWN, Mass., April 07, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data on zelicapavir, an oral, once-daily, N-protein inhibitor, in development for the treatment of (RSV) have been accepted for two oral presentations at the European Society of Clinical Microbiology & Infectious Diseases Global 2026 (ESCMID) being held April 17-21, 2025
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2190,"height":657,"url":"https://media.zenfs.com/en/business-wire.com/df501fb457761479f9fc4363bccb9707"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kgEiU94d3jQfS4fDRbakJw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI4OA--/https://media.zenfs.com/en/business-wire.com/df501fb457761479f9fc4363bccb9707","width":960,"height":288},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/jl8J3n_u0KAFFr63hvvZ7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MjA-/https://media.zenfs.com/en/business-wire.com/df501fb457761479f9fc4363bccb9707","width":1200,"height":360}},"lazy":false},{"type":"text","content":"WATERTOWN, Mass., April 07, 2026--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data on zelicapavir, an oral, once-daily, N-protein inhibitor, in development for the treatment of (RSV) have been accepted for two oral presentations at the European Society of Clinical Microbiology & Infectious Diseases Global 2026 (ESCMID) being held April 17-21, 2025 in Munich, Germany.","length":541,"tagName":"p"},{"type":"text","content":"The first oral presentation will include results from RSVHR, the Phase 2b study of zelicapavir in high-risk adults, which were announced in September 2025, showing about a week improvement in complete symptom resolution and a lower hospitalization rate, and featuring new findings demonstrating strong exposure multiples over the EC90. The second oral presentation will highlight new data confirming zelicapavir’s high clinical and functional barrier against antiviral resistance, generated from the Phase 2 study in pediatric patients, which was announced in September 2024.","length":575,"tagName":"p"},{"type":"text","content":"Details of the presentations are as follows:","length":44,"tagName":"p"},{"type":"text","content":"Presentation Title: Zelicapavir Decreases Symptom Duration, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of High-Risk Adults with RSVAbstract Number: 3963Date: April 18, 2026Time: 8:30 a.m. CEST / 2:30 a.m. EDTLocation: Hall A1-3Session Type: 2-hour Oral Ses...